Research analysts at StockNews.com began coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) in a research note issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Separately, HC Wainwright lowered their price objective on shares of CASI Pharmaceuticals from $12.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, May 15th.
Get Our Latest Stock Report on CASI Pharmaceuticals
CASI Pharmaceuticals Price Performance
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last issued its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.66). The company had revenue of $3.41 million for the quarter. CASI Pharmaceuticals had a negative net margin of 105.76% and a negative return on equity of 110.11%. As a group, sell-side analysts anticipate that CASI Pharmaceuticals will post -2.56 EPS for the current year.
Institutional Investors Weigh In On CASI Pharmaceuticals
An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Howland Capital Management LLC acquired a new stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned approximately 0.30% of CASI Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 22.23% of the company’s stock.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Read More
- Five stocks we like better than CASI Pharmaceuticals
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 3 Warren Buffett Stocks to Buy Now
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Read Stock Charts for Beginners
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.